Bayer's science symposium emphasises need for interdisciplinary exchanges

摘要

Advances in cancer therapy are ex- pected in the next few years thanks in particular to treatment using antibody-drug conjugates (ADCs) and multi-kinase inhibitors. This is the finding from a German research institute, TNS Emnid, survey of medical experts at the Science For A Better Life' symposium organised by Bayer.